- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-1-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 4 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.3: 11 residues within 4Å:- Chain A: E.181, P.182, V.224, L.231, N.232, N.346, G.348, C.413, V.414, S.415
- Ligands: NAG.26
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.6: 4 residues within 4Å:- Chain A: N.355, S.357
- Ligands: NAG-NAG.5, NAG-NAG.5
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.14: 8 residues within 4Å:- Chain E: V.224, L.231, N.232, N.346, C.413, V.414, S.415
- Ligands: NAG.41
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.15: 4 residues within 4Å:- Chain E: N.332, S.333, T.341
- Ligands: NAG-NAG.16
No protein-ligand interaction detected (PLIP)- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 32 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.18: 4 residues within 4Å:- Chain A: N.103, R.113, K.117, Y.161
Ligand excluded by PLIPNAG.19: 3 residues within 4Å:- Chain A: N.204, T.206, S.244
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: N.271, V.410
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain A: R.162, N.167
Ligand excluded by PLIPNAG.22: 1 residues within 4Å:- Chain A: N.361
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain A: T.267, H.299, N.301, R.412
Ligand excluded by PLIPNAG.24: 5 residues within 4Å:- Chain A: Q.263, N.265, V.302, S.303, R.412
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain A: N.308, T.363, W.364
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: N.232, N.416
- Ligands: NAG-NAG-BMA.3
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain A: E.57, N.58
- Chain B: S.17
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain B: N.126, Y.127
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain C: N.103
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain C: N.204, T.206, S.244
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain C: K.222, N.232, N.416
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain C: N.271
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain C: H.299, N.301, R.412
Ligand excluded by PLIPNAG.34: 1 residues within 4Å:- Chain C: N.361
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain C: K.304, N.308
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain C: Q.263, N.265, S.303, R.412, V.414
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain A: R.278
- Chain C: N.167
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain C: E.57, N.58
- Chain D: S.17
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain E: N.204, T.206, S.244
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain E: N.246, T.248
Ligand excluded by PLIPNAG.41: 4 residues within 4Å:- Chain E: Q.263, V.414, N.416
- Ligands: NAG-NAG-BMA.14
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain E: R.162, N.167
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain E: N.103, R.113, K.117
Ligand excluded by PLIPNAG.44: 5 residues within 4Å:- Chain E: T.267, H.299, N.301, T.383, R.412
Ligand excluded by PLIPNAG.45: 5 residues within 4Å:- Chain E: Q.263, N.265, V.302, S.303, R.412
Ligand excluded by PLIPNAG.46: 2 residues within 4Å:- Chain E: N.271, I.292
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain E: E.57, N.58
- Chain F: S.17
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain E: N.361
- Ligands: NAG-NAG.16
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain E: N.308
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xu, J. et al., Cryo-EM structure of HIV-1 Env BG505 DS-SOSIP in complex with broadly neutralizing bi-specific antibody CAP256L-R27 targeting the CD4-binding site and the V2-apex. To Be Published
- Release Date
- 2024-05-08
- Peptides
- HIV-1 BG505 DS-SOSIP gp120: ACE
HIV-1 BG505 DS-SOSIP gp41: BDF
Light chain of bi-specific antibody CAP256L-R27: GHJ
Heavy chain of bi-specific antibody CAP256L-R27: I - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EB
BD
DF
FG
HH
IJ
JI
X
SMTL ID : 8tni.1
Cryo-EM structure of HIV-1 Env BG505 DS-SOSIP in complex with broadly neutralizing bi-specific antibody CAP256L-R27 targeting the CD4-binding site and the V2-apex
HIV-1 BG505 DS-SOSIP gp120
Toggle Identical (ACE)HIV-1 BG505 DS-SOSIP gp41
Toggle Identical (DF)Light chain of bi-specific antibody CAP256L-R27
Toggle Identical (GH)Heavy chain of bi-specific antibody CAP256L-R27
Related Entries With Identical Sequence
4tvp.1 | 4zmj.1 | 5aco.1 | 5c7k.1 | 5cez.2 | 5cjx.1 | 5fyl.1 | 5t3x.1 | 5t3z.1 | 5thr.1 | 5u7m.1 | 5u7o.1 | 5utf.1 | 5uty.1 | 5v7j.1 | 5v8l.1 | 5v8m.1 | 5viy.1 | 5vj6.1 | 5w6d.1 | 6cm3.1 | 6crq.1 | 6de7.1 | 6did.1 | 6mn7.1 | 6mtj.1 | 6mtn.1 | 6mu6.1 | 6mu7.1 | 6mu8.1 more...less...6nf2.1 | 6nm6.1 | 6nnf.1 | 6nnj.1 | 6opa.1 | 6osy.1 | 6ot1.1 | 6oz4.1 | 6ozc.1 | 6pw6.1 | 6u0l.1 | 6u0n.1 | 6udj.1 | 6vi0.1 | 6vn0.1 | 6w03.1 | 6x96.1 | 6x97.1 | 6x98.1 | 6x9r.1 | 6x9r.2 | 6x9r.3 | 6x9s.1 | 6x9s.2 | 6x9s.3 | 6x9t.1 | 6x9t.2 | 6x9t.3 | 6x9u.1 | 6x9u.2 | 6x9u.3 | 6x9v.1 | 6x9v.2 | 6x9v.3 | 6xrt.1 | 7kde.1 | 7lo6.1 | 7lok.1 | 7lpn.1 | 7mxe.1 | 7pc2.1 | 7rai.1 | 7tfn.1 | 7tfo.1 | 7txd.1 | 7ucf.1 | 7uoj.1 | 8dp1.1 | 8dto.1 | 8e1p.1 | 8euu.1 | 8euv.1 | 8euw.1 | 8fis.1 | 8fk5.1 | 8fl1.1 | 8flw.1 | 8fyj.1 | 8g85.1 | 8g9w.1 | 8g9x.1 | 8g9y.1 | 8gas.1 | 8jtd.1 | 8jtm.1 | 8sal.1 | 8san.1 | 8saq.1 | 8sat.1 | 8sav.1 | 8sw3.1 | 8sw4.1 | 8tjr.1 | 8tjs.1 | 8tkc.1 | 8tl2.1 | 8tl3.1 | 8tl4.1 | 8tl5.1 | 8tng.1 | 8tnh.1 | 8tnu.1 | 8to7.1 | 8top.1 | 8tq1.1 | 8ttw.1